Sep 26 |
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
|
Sep 24 |
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
Sep 19 |
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
|
Sep 9 |
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
|
Aug 28 |
HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
Jul 29 |
HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
|
Jul 5 |
Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China
|
Jul 4 |
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
|
Jun 26 |
HUTCHMED to Announce 2024 Half-Year Financial Results
|
Jun 24 |
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
|